Difficulty: Medium
Average Score: 83%
Practice
A 52-year-old postmenopausal patient has evidence of low bone mineral density. She and her physician are considering therapy with raloxifene or a combination of conjugated estrogens and medroxyprogesterone acetate. Which of the following patient characteristics is most likely to lead them to select raloxifene?
Correct answer
D
Rationale
The correct answer is D) Strong family history of breast cancer. Raloxifene is a selective estrogen receptor modulator (SERM) that acts as an estrogen agonist on bone tissue, helping to prevent bone loss in postmenopausal women. It also has anti-estrogen effects on the breast tissue, making it a suitable choice for women with a strong family history of breast cancer as it may reduce the risk of developing breast cancer.
Option A) Previous hysterectomy is not a determining factor in selecting raloxifene over estrogen therapy. Estrogen therapy is usually recommended for women who have had a hysterectomy.
Option B) Recurrent vaginitis is not a factor that would influence the choice between raloxifene and estrogen therapy for bone health.
Option C) Rheumatoid arthritis does not specifically impact the decision between raloxifene and estrogen therapy in the context of bone health.
Educationally, understanding the rationale behind drug choices based on patient characteristics is crucial for healthcare providers to make informed decisions that align with the patient's medical history, risk factors, and treatment goals. It also highlights the importance of considering individual patient factors when selecting the most appropriate therapeutic option.
Option A) Previous hysterectomy is not a determining factor in selecting raloxifene over estrogen therapy. Estrogen therapy is usually recommended for women who have had a hysterectomy.
Option B) Recurrent vaginitis is not a factor that would influence the choice between raloxifene and estrogen therapy for bone health.
Option C) Rheumatoid arthritis does not specifically impact the decision between raloxifene and estrogen therapy in the context of bone health.
Educationally, understanding the rationale behind drug choices based on patient characteristics is crucial for healthcare providers to make informed decisions that align with the patient's medical history, risk factors, and treatment goals. It also highlights the importance of considering individual patient factors when selecting the most appropriate therapeutic option.